Comparative studies of drotaverine--acephyllinate (Depogen) and pentoxifylline (Trental).
Pentoxifylline is an orally active agent for the treatment of peripherial and cerebral vascular diseases. Pentoxifylline increases the deformability of red blood cells in vitro, reduces blood viscosity and decreases platelet aggregation and thrombus formation. Depogen has shown antiaggregatory effect both in vitro and in ex vivo. The inhibitory effect of Pentoxifylline was about 3-5 times weaker than that of Depogen. IC50 = 900/micrograms/ml for Depogén and 3600/micrograms/ml for Pentoxifylline on human platelet rich plasma. Depogen has shown ex vivo antiaggregatory effect on anesthetised rabbits, ID50 = 7 mg/kg in case of iv. administration, and ID50 = 300 mg/kg in case of orally administration. Both compound inhibit the release of platelet precoagulation factor, but the effect of Pentoxifylline was slighter.
Kapui
Z
Z
Research Centre of Pharmaceutical and Chemical Works CHINOIN, Budapest, Hungary.
Hermecz
I
I
Sarkadi
B
B
Szentmiklósi
P
P
Tardos
L
L
Blaskó
G
G
D000818:Animals; D002449:Cell Aggregation / Q000187:drug effects; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D004912:Erythrocytes / Q000187:drug effects*; D006801:Humans; D007962:Leukocytes / Q000187:drug effects*; D010208:Papaverine / Q000031:analogs & derivatives* / Q000494:pharmacology; D010431:Pentoxifylline / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010977:Platelet Factor 3 / Q000037:antagonists & inhibitors; D011817:Rabbits; D013806:Theophylline / Q000031:analogs & derivatives* / Q000494:pharmacology
D004338:Drug Combinations; D010975:Platelet Aggregation Inhibitors; D010977:Platelet Factor 3; C034813:drotaverine, acephyllinate drug combination; C005317:drotaverin; D013806:Theophylline; D010208:Papaverine; D010431:Pentoxifylline